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Abstract  Chikungunya  fever  is  a  tropical  vector-borne  disease  that  has  been  spreading  rapidly
around the  world  during  the  last  10  years,  and  which  has  been  usually  misdiagnosed  as  dengue.
Nowadays,  this  disease  is  increasing  in  Mexico,  mainly  in  the  southern  and  central  zones  of
the country,  being  signiﬁcantly  more  common  in  women,  children  and  young  adults  (28%  in  <  20
years of  age).  The  classical  presentation  includes  fever,  arthralgia,  polyarthritis,  back-pain,  and
skin rashes.  Although  symptoms  and  treatment  are  similar  to  those  for  dengue,  there  are  key
clinical features  to  differentiate  these  two  diseases.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Enfermedad  por  virus  de  chikungunya:  actualidad  en  México
Resumen  La  enfermedad  por  el  virus  chikungunya  es  una  enfermedad  tropical  transmitida  por
vector, que  en  los  últimos  10  an˜os  ha  tenido  una  gran  diseminación  mundial  y  ha  sido  históri-
camente  subdiagnosticada  debido  a  las  características  en  común  con  el  dengue.  Actualmente
la incidencia  en  México  ha  ido  en  aumento,  sobre  todo  en  el  centro-sur  del  país.  Es  más  común
en mujeres,  adultos  jóvenes  y  nin˜os  (28%  son  menores  de  20  an˜os).  El  cuadro  clínico  suele  pre-
sentarse con  ﬁebre,  artralgia,  poliartritis,  dolor  de  espalda,  cefalea  y  erupciones  cutáneas.  A
pesar de  que  el  tratamiento  es  sintomático  y  similar  al  del  dengue,  existen  datos  clínicos  clave
para diferenciarlas.
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. Introduction
he  term  ‘‘chikungunya’’  is  derived  from  the  word  kungun-
ala,  from  the  African  kimakonde  language,  which  means
‘one  who  slouches’’  in  reference  to  the  stooped  posture
dopted  by  the  people  because  of  the  unbearable  joint  and
uscular  pain1.
It  is  an  arboviral  infection  caused  by  the  chikungunya
irus  (CHIKV),  which  is  transmitted  by  the  bite  of  infected
edes  mosquitoes.  The  main  clinical  manifestations  are
ever,  arthralgia,  polyarthritis,  backache,  headache,  and
kin  rash2.  The  treatment  is  symptomatic,  with  the  appli-
ation  of  analgesics.
. History
he  ﬁrst  CHIKV  outbreak  was  reported  in  July,  1952,  in
n  epidemic  that  occurred  over  the  plateaus  of  Mawia,
akonde  and  Rondo,  now  Tanzania.  However,  retrospective
tudies  suggest  that  the  epidemic  of  CHIKV  has  occurred
n  Africa  for  centuries,  with  outbreaks  exported  to  Asia
nd  America  in  the  18th  and  19th  centuries  although  those
utbreaks  were  documented  as  dengue.  Some  terms  such
s  genoux,  dengue,  knokkelkoorts  (knuckles  fever),  by  the
nhabitants  of  Batavia,  aburokab  (fever  of  the  knees)  by  the
reeks,  and  3-day  fever  in  Calcutta,  have  been  given  to  this
pidemic1,3.
Testimony  of  this  is  the  classic  report  widely  cited  as  the
rst  description  of  the  dengue  epidemic  by  David  Bylon,  a
urgeon  in  the  city  of  Batavia  (Jakarta),  who  contracted  the
isease  and  wrote  the  following  in  1779:
‘‘It  was  on  May  25,  at  5:00  in  the  afternoon  when  I noted
that  while  I  chatted  with  two  good  friends  of  mine,  an
increased  pain  in  my  right  hand  and  forearm  joint  was
step  by  step  proceeding  way  up  toward  the  shoulder  and
then  continued  towards  all  my  limbs;  and  by  9:00  of  the
same  afternoon  I  was  already  in  bed  with  high  fever...
There  have  been  3  weeks  since...  I  was  hit  by  the  disease,
and  because  of  that  I  had  to  stay  home  for  5  days;  but
even  until  today,  I  have  a  continuous  pain  and  stiffness
in  joints  of  both  feet  with  discomfort  in  both  ankles,  so
much  that  when  I  wake  up  in  the  mornings,  or  sit  for  a
while  and  start  to  move  again,  I  cannot  do  it  very  well,
and  going  up  and  down  stairs  is  very  painful’’4.
This  report  of  febrile  illness  of  sudden  onset  with  joints
nvolved  suggests  that  the  disease  was  CHIKV.  That  same
ear  in  Cairo  and  Alexandria  (Egypt)  another  outbreak  of
he  disease  took  place  with  a  strong  resemblance  to  CHIKV,
n  which  attack  rates  reached  40-50%.  The  soil  of  these
lateau  is  highly  permeable,  so  local  residents  need  to  store
ater.  This  results  in  large  populations  of  Aedes  (Stegomyia)
egypti,  generally  considered  to  be  the  domesticated  form
f  A.  aegypti  which  efﬁciently  transmit  arboviruses,  such  as
ellow  fever  and  dengue.
The  virus  became  endemic  in  Africa  by  outbreaks  that
ccurred  in  Uganda,  Democratic  Republic  of  the  Congo,
imbabwe,  Senegal,  Nigeria,  South  Africa  and  Kenya.  Par-
icularly  in  Uganda,  it  was  found  that  the  arboreal  mosquito
edes  africanus  becomes  infected  naturally,  being  the  ﬁrst
vidence  of  the  jungle  CHIKV  enzootic  cycle3.
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After  the  outbreak  of  1952,  the  virus  was  spread  to  India
nd  countries  in  Southeast  Asia,  a  leader  in  epidemics  during
he  following  years.  The  ﬁrst  evidence  of  CHIKV  outside  of
frica  came  from  Bangkok,  Thailand,  where  the  virus  was
solated  in  1958  during  the  outbreak,  and  associated  with  the
ransmission  of  A.  aegypti,  followed  by  several  outbreaks
n  Cambodia,  Vietnam,  Malaysia  and  Taiwan.  On  the  other
and,  the  ﬁrst  epidemic  reported  in  India  was  in  Kolkata
formerly  Calcutta),  West  of  Bengal,  in  19631,3.
In  1964,  antibodies  were  detected  in  non-human  pri-
ates  (NHPs)  captured  in  the  current  Zimbabwe,  and  green
onkeys  were  shown  to  be  hosts  able  to  amplify  the
ransmission  of  CHIKV  using  mosquitoes.  Since  then,  sev-
ral  studies  have  conﬁrmed  the  role  of  the  NHPs  and  A.
fricanus,  A.  furcifer  and  other  arboreal  mosquitoes  as
nzootic  vectors1.
.1.  Recent  outbreaks
n  2004,  a new  outbreak  emerged,  which  started  at  the  coast
f  Kenya  (Mombasa);  in  the  next  two  years  it  spread  to
ertain  islands  in  the  Indian  Ocean,  such  as  The  Reunion,
omoros,  Mayotte,  Madagascar,  Mauritius,  Seychelles  and
aldives.  It  is  estimated  that  500,000  cases  occurred  since
he  spring  of  2004  until  the  summer  of  the  20065,6.
The  epidemic  spread  from  the  islands  of  the  Indian  Ocean
o  India,  where  major  outbreaks  occurred  in  2006.  Once
ntroduced,  CHIKV  spread  to  17  of  the  28  states  of  India,
nfecting  more  than  1.39  million  people  before  the  end
f  the  year.  The  outbreak  in  India  continued  until  2010,  with
he  emergence  of  new  cases  in  non-affected  areas  during  the
nitial  phase  of  the  epidemic.  Outbreaks  also  spread  from
ndia  to  the  Andaman  and  Nicobar  Islands,  Sri  Lanka,  the  Mal-
ives,  Singapore,  Malaysia  and  Indonesia  through  travelers
ho  were  in  the  viremic  phase5.
Concern  over  the  spread  of  CHIKV  peaked  in  2007,
hen  it  was  detected  that  the  virus  was  spreading  in  an
utochthonous  form  (human-mosquito-human)  in  the  North
f  Italy,  after  being  introduced  by  a  viremic  traveler  retur-
ing  from  India.  The  Italian  Ministry  of  Health  conﬁrmed  160
ases  in  Rabean  of  which  an  83-year-old  man  died.  A  year
ater,  the  ﬁrst  imported  case  was  detected  in  Canada5,6.
In  2010,  two  cases  not  imported  were  detected  in  the
ar  region,  in  southeast  France;  other  cases  were  imported
n  Australia,  United  States  and  Taiwan,  while  in  October,
en  cases  were  reported  in  southern  China  in  the  city  of
ongguan.  At  the  end  of  that  year,  a  case  was  diagnosed  in
a  Rioja  (Spain)  in  a  person  who  had  visited  the  North  of
ndia  shortly  before.  Subsequently,  in  September  of  2013,  a
ase  was  detected  at  the  coast  of  Valencia  in  a surfer  who
ad  spent  the  summer  in  the  Senegal  coast5.
In  2013,  the  Panamerican  Health  Organization  (PAHO)
eported  the  ﬁrst  autochthonous  cases  in  America,  speci-
cally  on  the  island  of  St.  Martin,  in  the  Caribbean.  In  May
014,  it  reported  local  circulation  of  the  disease  in  several
slands  of  the  Caribbean  such  as  Antigua  and  Barbuda,  Haiti,
ominican  Republic  and  St.  Kitts,  among  others7.  That  same
ear  the  ﬁrst  case  in  Mexico  occurred  in  a  39-year-old  woman
ho  traveled  to  the  Caribbean  on  May  21st  passing  through
he  islands  of  St.  Thomas,  St.  Martin  and  St.  Kitts,  to  reach
ntigua  and  Barbuda,  where  she  remained  until  May  28th5,8.
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4Figure  1  Number  of  chikungunya  fever  cases  by  group  of  a
Studies  on  CHIK  virus  in  different  geographical  areas  show
the  prevalence  of  three  lineages  with  genotypic  and  anti-
genic  distinctions.  In  Africa,  two  genotypes  were  attributed
to  epidemics  and  they  kept  the  name  of  the  region  where
they  appeared,  West  Africa  (WA)  and  the  Eastern  Central
Region  of  South  Africa  (ECSA);  and  the  Asian  genotype  was
represented  throughout  Asia.  However,  the  2005-2006  epi-
demics  included  the  introduction  of  the  ECSA  genotype  to
the  Asian  continent  for  the  ﬁrst  time5.
3. Epidemiology
Currently,  CHIKV  disease  has  had  a  wide  distribution  in
tropical  and  subtropical  countries  around  the  world,  high-
lighting  the  Asian  and  African  continents,  the  Western
Paciﬁc,  the  Caribbean,  South  America  and,  more  recently,
North  America1.
In  Mexico,  epidemiological  surveillance  started  formally
until  2014.  However,  in  the  data  reported,  a  distinction
between  suspected  and  conﬁrmed  cases  has  been  not  made.
In  that  year,  data  revealed  that  all  groups  of  age  were
exposed  to  CHIKV.  The  most  affected  group  was  that  of  25  to
44  years  of  age,  with  a  34.8%.  Nevertheless,  the  population
<  19  years  of  age  represented  28%  of  the  total  population,
which  highlights  the  importance  of  the  disease  in  pediatric
population  (Figure  1)9.
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Figure  2  Mexican  states  with  the  highest  frequency  of  chikunguny
12 (Source:  DGEPI/Boletín  epidemiológico  semanal:  week  49  of  2015Mexico,  2014  (Source:  DGEPI/Anuarios  de  morbilidad  2014).
In  2015,  there  was  a  signiﬁcant  increase  in  reported
ases,  with  a  total  of  11,394  cases  (accumulated  until
ecember  12),  compared  to  222  cases  in  2014.  In  terms  of
eographical  location  (Figure  2),  mostly  affected  states  are
n  the  South  of  the  country,  which  coincides  with  the  trend
f  the  vectors  to  settle  in  warm  and  humid  zones10.  Proba-
ly,  low  educational  level  in  some  of  these  states  conditions
 minor  spreading  and  practice  of  preventive  measures.
Women  have  been  notably  more  affected  than  men,
hich  may  be  explained  with  the  cultural  custom  of  women
o  work  at  home,  where  the  main  vector  (A.  aegypti)  of
HIKV  sets,  usually  associated  with  deposits  of  water.  In
exico,  in  2015  (up  to  12/12/15),  the  number  of  cases
eported  by  gender  were  7,285  female  (65%)  and  3,915  male
35%)4,10,11.
In  2015,  the  highest  transmission  of  CHIKV  occurred  dur-
ng  the  summer  and  then  decreased  over  the  course  of
utumn,  unlike  dengue  which  increased  to  its  highest  preva-
ence  in  November  (Figure  3)10.
.  Etiologyhe  CHIKV  belongs  to  the  genus  Alphavirus, which  belongs  to
he  family  Togaviridae. It  is  a small  size  (65-70  nm  diameter)
ingle-stranded  RNA  of  positive  sense  virus,  with  a  symmet-
ical  icosahedral  capsid,  enveloped  by  80  peaks  with  trimers
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eekly epidemiological  bulletins  available  in  2015).
f  E1  and  E2  glycoproteins  in  each  one  of  them.  E2  glyco-
rotein  complexes  join  to  unknown  cell  receptors  and  then
nter  the  cell  by  endocytosis.  The  E1  glycoprotein  includes
 fusion  peptide  which  promotes  the  release  of  nucleocap-
ides  in  the  cytoplasm  of  host  cell  when  it  is  exposed  to  low
H  in  endosomes1.
. Mutations
 mutation  was  detected  in  90%  of  the  viruses  isolated  from
he  CHIKV  outbreak  on  the  island  of  Reunion,  France,  which
egan  in  March  2005  and  ended  in  April  2006  registering
44,000  cases  (123  severe  cases,  41  cases  of  mother  to
hild  transmission,  and  203  associated  deaths).  The  muta-
ion  occurs  at  the  level  of  residue  226  of  the  E1  glycoprotein
f  the  fusion  membrane  (E1-A226  V).  It  is  postulated  that  this
ould  facilitate  the  replication  and  transmission  of  the  virus
y  reducing  its  dependence  on  cholesterol1.
. Vectors
.  aegypti  and  A.  albopictus  are  invasive  species  that  inhabit
ropical  and  temperate  regions.  Their  ability  to  breed  in
rtiﬁcial  containers  facilitates  their  passive  spread  through
he  main  routes  of  transport.  A.  aegypti  has  domestic  and
eridomestic  habits.  Usually,  it  does  not  occupy  territories
ocated  more  than  1,000  m  above  the  sea  level,  although
t  has  occasionally  been  found  up  to  2,400  m.  In  contrast,
.  albopictus  has  jungle  habits  and  proliferates  in  wild  envi-
onments,  and  it  is  responsible  for  the  transmission  of  the
irus  in  rural  or  semi-urban  areas;  this  is  due  to  the  adaptive
utations  of  the  viral  genome,  which  increase  its  replication
n  this  vector.  Aedes  eggs  resist  desiccation  and  extreme
emperatures,  staying  viable  from  7  months  to  a  year,
hich  signiﬁcantly  hinders  the  eradication  of  the  vector.  In
merica,  many  regions  are  susceptible  to  invasion  and
pread  of  this  virus,  and  the  recent  emergence  of  urban
pidemics  of  dengue  fever  in  South  America  highlights  the
otential  danger  of  chikungunya  fever12,13.
The  main  vectors  of  the  CHIKV  in  Asia  and  Indian  Ocean
re  also  Aedes  aegypti  and  Aedes  albopictus, but  other
b
s
iungunya  fever  during  2015  (Source:  approximate  data  with  the
pecies  of  Aedes  (A.  furcifer,  A.  vittatus,  A.  fulgens, among
thers)  can  also  transmit  the  infection12.
. Transmission
he  transmission  cycle  requires  infection  of  female
osquitoes  through  the  blood  of  infected  people.  After  an
dequate  extrinsic  incubation  period  (at  least  48  h),  it  is
ransmitted  to  another  host  through  the  bite  of  infected
emale  mosquitoes.  The  hosts  remain  viremic  approximately
ntil  fever  has  gone10,12.
During  outbreak  periods,  humans  are  the  main  reser-
oir  of  the  virus,  which  remains  in  circulation  between
osquitoes  and  humans  while,  in  interepidemic  periods,
arious  vertebrates  have  been  implicated  as  reservoirs
non-humans  primates,  rodents,  birds  and  small  mam-
als).  Vertical  viral  transmission  and  through  breastfeeding
as  been  documented;  furthermore,  when  infection  occurs
uring  delivery  or  shortly  before,  the  transmission  rate
ncreases  to  levels  close  to  50%.  There  is  a  possibi-
ity  of  transmission  through  transfusion  of  blood  or  blood
roducts13.
. Pathophysiology
he  virus  anchors  to  the  cells  with  its  E2  glycoprotein,
enerating  its  endocytosis;  later,  its  RNA  acts  as  mRNA  to
ynthesize  four  non-structural  proteins,  which  will  inﬂuence
he  production  of  other  proteins  required  for  replication14.
rohibitine  has  been  identiﬁed  as  a  receptor  for  the  virus15.
HIKV  evades  the  immune  system  by  means  of  the  pro-
ein  nsP2,  which  hydrolyzes  RNA  polymerase,  inhibiting  the
ranscription  of  some  genes  involved  in  antiviral  response.
acrophages  and  sinusoidal  endothelium  of  the  liver  have
een  identiﬁed  as  cellular  reservoirs,  and  joints,  muscle,
ermis  tissue  and  ﬁbroblasts  are  targets  to  the  virus.  The
resence  of  inﬂammatory  inﬁltrate  with  viral  replication  has
een  documented  in  skeletal  muscle  and,  in  some  cases,  in
ynovial  ﬂuid12,16,17.
Inﬂammation  of  joints  is  mainly  caused  by  adaptive
mmune  response.  IgM  antibodies  are  present  as  early  as
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2  days  after  the  onset  of  symptoms,  and  persist  for  weeks
to  months,  while  IgG  is  usually  detected  when  the  virus  is
eliminated,  and  persist  for  many  years,  which  prevents  the
reinfection  of  virus13,18.  The  antibody  response  is  mainly  of
the  IgG3  isotype  (neutralizing)  and  it  is  associated  with  the
elimination  of  the  virus13,  although  the  persistence  of  anti-
CHIKV  IgM  in  serum,  and  of  the  virus  in  tissues  of  joints  and
in  the  endothelial  reticulum  system  may  explain  the  chronic
arthropathy 12,14,16,19.
In  the  acute  phase,  the  infection  triggers  the  release  of
various  cytokines,  such  as  IL-6,  G-CSF,  GM-CSF,  MCP1,  TNF-
,  CXCL9,  CCL2  and  CXCL10,  persisting  only  IL-17,  IL-6,  and
GM-CSF,  the  latter  two  associated  with  arthralgia.  There
is  also  an  increase  in  IL-18  induced  by  the  Th1  response.
This  interleukin  has  a  negative  feedback  because  it  induces
the  production  of  INF,  which  in  turn  induces  the  increase
in  the  IL-18  binding  protein  (IL-18BP),  a  natural  regula-
tor  of  IL-1820.  With  respect  to  NK  cells,  these  overexpress
the  CD94NKG2C  receptor,  although  the  mechanism  through
which  it  interferes  with  the  infection  is  still  unknown5.  It
has  been  shown  that  the  increase  in  IL-1 and  IL-6  is  related
with  a  poor  outcome.
The  virus  may  spread  to  the  CNS,  showing  tropism
towards  choroid  plexuses,  CSF,  ependymal  cells  and
meninges12,19.  Regarding  pregnancy,  it  has  not  been  found  in
placental  tissue.  Increasing  age  is  a  risk  factor  for  develop-
ing  serious  illness;  however,  in  children,  newborn  are  more
susceptible12,13,16.
9. Clinical features
After  intradermal  inoculation  of  the  virus  by  the  mosquito,
72  to  97%  of  the  patients  develop  the  symptoms  after  an
incubation  period  that  can  vary  from  1  to  12  days  (on  average
lasts  from  2  to  4 days)13,16.  Initially,  the  disease  is  character-
ized  by  a  sudden  onset  of  high  fever  with  myalgia  and  severe
arthralgia  which  may  even  interfere  with  sleep.  Headache,
photophobia,  rash,  weakness,  fainting,  confusion  or  deﬁcit
attention  disorders  can  occur16,19.
Fever  starts  suddenly  and  usually  exceeds  39 ◦C,  remains
constant  for  2-7  days  until  it  suddenly  stops13.  Less  than  33%
of  the  patients  have  a  second  febrile  peak21.
Joint  affection  is  present  in  70  to  100%  of  the  patients,
and  it  is  characterized  by  severe  arthralgia  with  subacute
to  chronic  arthritis,  joint  effusion,  stiffness  and,  in  some
cases,  tenosynovitis  may  appear13,21.  The  condition  tends
to  be  symmetrical,  mainly  in  the  interphalangeal  joints  of
hands  and  feet,  metacarpal,  metatarsophalangeal,  ankles,
wrists  and  knees12,13,16.  The  joint  signs  and  symptoms  are
usually  resolved  within  1-2  weeks;  however,  in  12-57%  of
the  patients,  arthralgias  persist  in  the  same  places  for  more
than  3  months  up  to  years,  ﬂuctuating  in  intensity  and  dura-
tion.  People  over  45  years  with  more  severe  pain  initially,
and  especially  those  who  have  pre-existing  osteoarthritis,
are  the  most  susceptible  patients  to  chronic  affection  by
CHIKV13,17.
Since  the  onset  of  fever  until  5  days  later,  50%  of
the  patients  develop  vesicular  or  bullous  dermatosis  with
desquamation,  or  maculopapular  and  petechial  exanthema
which  is  sometimes  itchy  and  disappears  with  pressure  (more
often  in  adults);  it  affects  the  trunk,  and  can  extend  to
a
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alms,  soles  and  face.  It  tends  to  be  ﬂeeting  but  it  may
ersist  over  2  days13,21,22.  Hyperemia  of  the  outer  ear,  which
eﬂects  chondral  inﬂammation  possibly  related  to  infection
y  CHIKV,  is  also  observed19.
Fifty  percent  of  pediatric  patients  has  1  or  2  of  the  fol-
owing  symptoms:  convulsions,  loss  of  stool  consistency  or
eripheral  cyanosis21,22. Neurologic  complications  are  fre-
uent  causes  of  hospitalization  in  these  patients  with  CHIKV
nfection,  and  these  are  mainly  febrile  convulsions,  viral
ncephalitis  and  acute  encephalopathy19.
In  a  study  conducted  in  pregnant  women,  in  La  Reunion,
rance,  CHIKV  infection  was  not  associated  with  an
ncreased  frequency  of  abortions,  but  intrapartum  verti-
al  transmission  or  congenital  malformations  have  been
bserved.  In  the  ﬁrst  case,  after  the  incubation  period,  the
hild  has  fever  (79%),  rash  (82%),  and  peripheral  edema
58%);  regarding  congenital  malformations,  a  slight  increase
n  the  closure  defects  of  the  neural  tube,  chromosomal
bnormalities,  soft  palate  and  cardiac  defects  (42%)  were
bserved  in  children  of  women  who  were  infected  by  CHIKV
uring  pregnancy,  although  these  data  had  no  statistical
igniﬁcance  to  establish  a  causal  relationship4,22.  Cardiac
efects  include  myocardial  hypertrophy,  ventricular  dys-
unction,  pericarditis  and  dilation  of  the  coronary  arteries22.
Among  the  rare  manifestations  of  CHIKV  infection
rehemorrhaging,  such  as  conjunctival  injection  and  bleed-
ng  of  the  higher  or  lower  digestive  tract,  not  necessarily
elated  to  the  degree  of  thrombocytopenia.  Also,  myocardi-
is,  Guillain-Barré  Syndrome,  Raynaud’s  disease,  loss  of
uditory  acuity  (related  to  the  chondritis),  uveitis  or  infec-
ious  retinitis  have  been  observed13,18.
0. Conﬁrmatory diagnosis
he  gold  standard  for  conﬁrmation  of  chikungunya  fever
s  real  time  polymerase  chain  reaction  (RT-PCR)  directed
oward  the  gene  of  the  non-structural  protein  of  CHIKV
NSP1)  or  the  gene  of  the  viral  envelope  of  CHIKV  (E),  either
n  blood  or  synovial  ﬂuid21.
Other  methods  to  conﬁrm  the  diagnosis  are  the  detection
f  response  to  antibodies  with  ELISA,  indirect  immunoﬂuo-
escence,  or  reverse  transcription  loop-mediated  isothermal
mpliﬁcation  (RT-LAMP)8. However,  although  the  anti-CHIKV
gM  appears  after  2-3  days  since  onset  of  symptoms,  titers  do
ot  reach  detectable  concentrations  by  ELISA  until  the  ﬁrst
r  second  week,  and  may  be  present  until  a year  later5,23.
Speciﬁc  IgG  for  CHIKV  rises  10-13  days  after  the  onset
f  symptoms  and  persists  with  high  titers  for  years,  pre-
ominantly  in  the  form  of  IgG31. The  persistence  of  high
iters  of  immunoglobulins  and  its  correlation  with  chronic
isease  suggest  an  impaired  antigenic  depuration  in  these
atients22.
Hematic  cytometry  often  shows  leukopenia  and
ometimes  very  mild  thrombocytopenia  (100,000
latelets/mm3).  Unlike  other  viral  diseases,  markers
f  inﬂammation,  such  as  the  sedimentation  rate  of  erythro-
ytes  and  C-reactive  protein,  tend  to  be  high,  and  there  is
lso  an  increase  in  hepatic  transaminases.
Joint  radiographs  show  no  alterations  except  in  the
hronic  condition  after  1  year,  in  which  there  are  signs  of
rosive  arthritis  and  reduction  of  the  articular  space8.
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Table  1  Clinical  comparison  between  fever  by  dengue  and
by chikungunya.
Clinical  features  Chikungunya  fever  Dengue
Fever  +++  ++
Myalgia  +  ++
Arthralgia  +++  +/-
Rashes  ++  +
Blood dyscrasia  +/-  ++
Shock -  +/-
Leukopenia  ++  +++
Lymphocytopenia +++  ++
Neutropenia  +  +++
Thrombocytopenia  +  +++
Average frequency of symptoms from studies where both
diseases were compared; + + + = 70-100% of patients; + + = 40-
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Adapted from OPS/OMS. Preparation and response against
Chikungunya virus in the Americas, 2010 (reference 15).
Since  there  are  often  difﬁculties  to  perform  the  con-
rmatory  diagnosis  of  this  disease,  the  PAHO  suggests  the
ollowing  deﬁnitions24:
Suspected  case: patient  with  fever  >  38 ◦C  (101 ◦F)  and
evere  arthralgia  or  arthritis  of  acute  onset  not  explained
y  other  medical  conditions,  and  that  endemic  or  epidemic
reas  have  been  affected  during  the  two  weeks  prior  to  the
nset  of  symptoms.
Conﬁrmed  case:  suspected  case  with  a  positive  speciﬁc
est  for  CHIKV  (viral  isolation,  RT-PCR,  IgM,  or  a  four-fold
ncrease  in  titers  of  antibodies  for  chikungunya).
1. Differential diagnosis
engue  is  the  most  alike  and  most  often  confused  disease
ith  chikungunya  fever,  partly  because  they  share  the  same
ector  (A.  aegypti)  and,  therefore,  its  same  geographic
pace.  The  most  important  clinical  data  to  differentiate
t  with  dengue  is  the  severe  polyarthralgia,  which  is  much
ore  frequent  in  chikungunya  fever;  however,  it  should  also
e  considered  that  it  shows  a  more  abrupt  start,  and  a  higher
ut  of  less  duration  fever  than  dengue.  Rashes,  conjunctival
njections  and  arthralgias  are  more  frequent  in  chikungunya
ever  than  in  dengue  (Table  1)16.
Other  laboratory  data  for  the  differential  diagnosis  are
ormocytic  normochromic  anemia,  hemoconcentration  and
hrombocytopenia  and  neutropenia,  which  are  usually  found
n  dengue  and  not  in  chikungunya  fever,  in  which  lymphope-
ia  is  more  common16.
Zika  virus  infection  is  a  new  Aedes  transmitted  disease
hat  is  spreading  aggressively  in  Africa,  South  and  Cen-
ral  America.  Its  clinical  features  are  similar  to  those  of
hikungunya  fever  and  dengue;  but  maculopapular  rash,
on-purulent  conjunctivitis  are  seen  more  often  in  Zika
irus  infection.  Of  these  three  entities,  Zika  virus  infec-
ion  has  the  higher  rate  of  neurological  and  teratogenic
omplications,  particularly  Guillain-Barre  syndrome  and
icrocephalus,  respectively.  It  is  very  important  to  make
 conﬁrmatory  diagnosis  by  RT-PCR25--27.
Leptospirosis  should  be  discarded  in  patients  with  a  his-
ory  of  contact  with  water,  mud,  or  rodents  in  an  endemic
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rea.  In  this  disease,  it  is  common  to  ﬁnd  serious  myal-
ia  in  gastrocnemius  muscles,  with  or  without  oliguria
nd  jaundice,  neutrophilia  and  elevated  titers  of  creatine
hosphokinase13.
To  clinically  rule  out  malaria,  the  febrile  pattern  should
e  observed,  which  tends  to  be  periodic  in  this  pathology.
heumatic  fever  should  also  be  considered  if  the  disease
resents  an  asymmetric  and  migratory  polyarthritis  that
nvolves  mainly  the  large  joints,  and  complies  with  the  Jones
riteria4.
In some  parts  of  the  world  there  are  other  endemic
rthritogenic  alpha  viroses.  The  Mayaro  fever  is  typical  of
orest  areas  and  has  a  very  similar  presentation  than  chikun-
unya  fever,  although  it  shows  a  little  less  frequency  in
oint  involvement  (50-90%);  it  also  has  peripheral  edema
58%),  retroorbital  headache  (40-60%),  dizziness  (25%),  sore
hroat  (18%),  lymphadenopathy  (17%),  vomiting  (4-14%),
iarrhea  (9%),  and  gingivorragia  (5%)20.  Other  types  of
ever  by  alphavirus  with  very  similar  symptoms  are  caused
y  the  Ross  River  virus  and  the  Barmah  Forest  virus  in
ustralia  and  some  Paciﬁc  Islands,  the  Onyong-nyongvirus
n  Africa,  and  the  Pogostavirus  in  Finland,  among  others.
herefore,  it  should  be  considered  if  there  is  a  history  of  a
ecent  trip  to  or  of  origin  from  any  of  these  sites,  although
reatment  does  not  vary  much16.
2. Treatment
here  is  still  no  speciﬁc  or  effective  antiviral  treatment
hich  reduces  the  therapeutic  measures  to  physical  me-
hods,  and  the  administration  of  acetaminophen  (symp-
omatic  treatment)  for  treating  fever3,7.  If  acetaminophen
oes  not  work,  NSAIDs  or  narcotics  can  be  used28.  Research
s  currently  carried  out  on  treatments  with  CHIKV  antibod-
es,  IFN-, chloroquine  and  rivabirin;  the  latter  has  been
sed  in  some  severe  forms  but  its  effectiveness  has  not  been
onﬁrmed8,12,15.  Chloroquine  could  interfere  with  the  entry
f  the  virus  to  cells,  while  rivabirin  is  an  inhibitor  of  viral
eplication28.
There  are  other  drugs,  but  their  effectiveness  is  still
ot  evaluated  in  humans.  The  use  of  inhibitors  of  CCL2
as  reduced  the  inﬂammatory  inﬁltrate  in  muscle  and
oints  in  mice  infected  with  CHIKV19.  For  chronic  rheumatic
anifestations  and  polyarthritis  that  last  more  than  2-3
onths,  the  use  of  antirheumatics  such  as  methrotrexate
s  recommended12.
3. Prognosis
hikungunya  fever  has  a  very  low  mortality  rate  (1  in  1,000);
owever,  the  recovery  can  be  prolonged  and  arthralgia
ay  persist  for  months  or  even  years12,19. Pediatric  and
lderly  patients  are  the  groups  with  most  risk  of  dying
ecause  CHIKV,  being  the  main  causes  of  death  hepatitis
nd  encephalitis  in  childhood,  and  heart  failure  and  multiple
rgan  failure  in  the  eldery16,17.4. Prevention
hikungunya  fever  prevention  measures  are  based  on  avoid-
ng  mosquito  stings,  killing  the  mosquitoes  and  avoiding  the
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formation  of  A.  aegypti  breeding  places;  just  as  for  other
diseases  transmitted  by  these  vectors5.
The  evasion  of  mosquito  bites  can  be  done  in  different
ways,  using  topic  repellents  such  as  n-diethyl-m-toluamide
(DEET),  which  in  children  is  recommended  in  concentrations
below  30%  and  should  be  applied  directly  on  the  exposed  skin
avoiding  contact  with  mucous  membranes;  or  environmental
repellents  (insecticides,  such  as  permethrin,  so  long  sleeves
that  can  be  sprayed  with  (resists  4-5  washes);  avoiding  the
use  of  perfumes  that  attract  mosquitoes;  installation  of  air
conditioning,  mosquito  nets  in  windows  and  beds13.
The  elimination  of  the  vector  can  be  done  with  insec-
ticides  or  physical,  or  biological  methods;  however,  at
endemic  areas,  it  is  easier  to  avoid  the  accumulation  of
water  and  waste,  periodically  emptying  containers  that
accumulate  water  in  yards.  If  accumulation  cannot  be
avoided,  a  light  oil  ﬁlm  can  prevent  the  deposit  of  eggs,  or
a  larvicide  such  as  temephos  can  be  used.  There  are  some
studies  in  cities  of  Vietnam  where  they  promoted  the  pro-
liferation  of  Copepods,  a  group  of  small  crustaceans  that
eat  mosquitoes,  and  they  obtained  positive  results  in  the
regulation  of  mosquitoes  in  the  urban  zone,  and  in  dengue
incidence29.
There  have  been  some  attempts  to  develop  chikungunya
vaccines.  The  US  Navy  has  developed  a  promising  attenuated
vaccine  that  appeared  to  be  safe  and  effective,  but  research
has  been  discontinued  because  the  military  interests  of  this
institution  have  been  modiﬁed.  Inactivated  vaccines  with
good  protective  response  for  CHIKV,  such  as  the  detergent-
inactivated  vaccine  and  the  formalin-inactivated  vaccine,
have  also  been  developed  but  there  is  still  not  enough
support  of  clinical  research.  Recently,  a  chikungunya  virus-
like  particle  vaccine  and  a  recombinant  measles-virus-based
chikungunya  one  have  been  tried,  each  one  in  a  short  phase
I  trial  (25  and  26  patients,  respectively),  in  which  both
showed  the  induction  of  chikungunya  virus  neutralizing  anti-
bodies  in  100%  of  the  patients.  Further  investigation  on
these  potential  chikungunya  vaccines  is  needed.  Aside  from
preventing  the  long-lasting  effects  of  the  disease,  a  chikun-
gunya  virus  vaccine  will  reduce  the  economic  and  social
impact  that  the  disease  has  in  endemic  countries  due  to
health  care  costs,  loss  of  working  days  and  impairment  in
tourism,  which  is  a  very  important  source  of  income  in  a  lot
of  countries17,30.
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